BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30545922)

  • 21. Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Umino K; Fujiwara SI; Minakata D; Yamamoto C; Meguro A; Matsuyama T; Sato K; Ohmine K; Izumi T; Muroi K; Kanda Y
    Leuk Lymphoma; 2019 Mar; 60(3):734-741. PubMed ID: 30188236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
    Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I
    Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
    Lugtenburg P; Avivi I; Berenschot H; Ilhan O; Marolleau JP; Nagler A; Rueda A; Tani M; Turgut M; Osborne S; Smith R; Pfreundschuh M
    Haematologica; 2017 Nov; 102(11):1913-1922. PubMed ID: 28935843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Picture in clinical hematology].
    Hatsuse M; Shimazaki C; Yumiba T
    Rinsho Ketsueki; 2013 Jan; 54(1):1. PubMed ID: 24015417
    [No Abstract]   [Full Text] [Related]  

  • 25. [Vocal cord paralysis secondary to vincristine].
    Nafil H; Tazi I; Mahmal L
    Rev Neurol (Paris); 2012 May; 168(5):464-5. PubMed ID: 22387202
    [No Abstract]   [Full Text] [Related]  

  • 26. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
    Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
    Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
    Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
    Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of diffuse large B-cell lymphosarcoma with involvement of bone marrow in an old female patient].
    Zamiatina VI; Kravchenko SK; Giliazitdinova EA; Magomedova AU; Vorob'ev IA; Gotman LN; Kaplanskaia IB; Kesel'man SA; Obukhova TN; Sakhibov IaD; Shevelev AA; Kremenetskaia AM
    Ter Arkh; 2008; 80(7):54-7. PubMed ID: 18763597
    [No Abstract]   [Full Text] [Related]  

  • 29. Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly.
    Khan Y; Brem EA
    Curr Hematol Malig Rep; 2019 Aug; 14(4):228-238. PubMed ID: 31228094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms.
    Lapa C; Knott M; Rasche L; Herrmann K; Buck AK; Rosenwald A
    Eur J Haematol; 2014 Dec; 93(6):545-6. PubMed ID: 24612353
    [No Abstract]   [Full Text] [Related]  

  • 31. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
    Hosoi M; Yamamoto G; Imai Y; Kurokawa M
    Ann Hematol; 2010 Feb; 89(2):207-8. PubMed ID: 19582454
    [No Abstract]   [Full Text] [Related]  

  • 32. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
    Olszewski AJ; Reagan JL; Castillo JJ
    Am J Hematol; 2018 Jan; 93(1):E1-E3. PubMed ID: 28960532
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era.
    Cassidy RJ; Jegadeesh N; Switchenko J; Danish H; Esiashvili N; Flowers CR; Khan MK
    Leuk Lymphoma; 2016 Aug; 57(8):1876-82. PubMed ID: 26759182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
    Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.
    Xiao J; Du S; Dai G; Gao G; Yang D; Zhao H
    Sci Rep; 2017 May; 7(1):1905. PubMed ID: 28507339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tiny transformed diffuse large B cell lymphoma localized to the left conjunctiva.
    Harada N; Tagami M; Koh H; Ohsawa M; Hino M; Nakamae H
    Int J Hematol; 2021 Oct; 114(4):413-414. PubMed ID: 34424492
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
    Nakayama S; Matsuda M; Adachi T; Sueda S; Ohashi Y; Awaji S; Hashimoto S; Matsumura I
    Platelets; 2019; 30(5):637-645. PubMed ID: 30047815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.
    Yamamoto W; Nakamura N; Tomita N; Takeuchi K; Ishii Y; Takahashi H; Watanabe R; Takasaki H; Motomura S; Kobayashi S; Yokose T; Ishigatsubo Y; Sakai R
    Leuk Lymphoma; 2014 Dec; 55(12):2721-7. PubMed ID: 24528218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.
    Falduto A; Cimino F; Speciale A; Musolino C; Gangemi S; Saija A; Allegra A
    Blood Rev; 2017 Jul; 31(4):235-249. PubMed ID: 28262268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited-stage diffuse large B-cell lymphoma: current management and challenges.
    Zhang XY; Collins GP; Cutter DJ; Eyre TA
    Br J Haematol; 2021 Aug; 194(3):508-517. PubMed ID: 33618434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.